The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 2, 2014, Pages 148-154

  Musiime, Victor ^a   Fillekes, Quirine ^b   Kekitiinwa, Adeodata ^c   Kendall, Lindsay ^d   Keishanyu, Rosette ^a   Namuddu, Rachel ^c   Young, Natalie ^d   Opilo, Wilfred ^a   Lallemant, Marc ^e   Walker, A Sarah ^d   Burger, David ^b   Gibb, Diana M ^d  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MULAGO HOSPITAL   (Uganda)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

Africa; children; HIV; lopinavir ritonavir; pharmacokinetics

Indexed keywords

LOPIMUNE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

AFRICA; AREA UNDER THE CURVE; ARTICLE; CAREGIVER; CHILD; CHILDHOOD DISEASE; CONFIDENCE INTERVAL; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MINITAB FORMULATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYRUP; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UGANDA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTI-HIV AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DRUG COMPOUNDING; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LOPINAVIR; MALE; RITONAVIR; TABLETS; UGANDA; WORLD HEALTH ORGANIZATION;

EID: 84901331937     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000135     Document Type: Article

References (12)

1. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach: 2010 Revision. Geneva, Switzerland: World Health Organisation, 2010. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/index. html. Accessed December, 2011.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS World AIDS Day Report 2012. Available at: http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2012/gr2012/JC2434-worldaidsday-results-en. pdf. Accessed April 5, 2013.
3. EMA. Kaletra; Summary of Product Characteristics. 2012. Available at: http://www.ema.europa.eu/docs/en-gb/document-library/epar-product-information/ human/000368/wc500039043.pdf. Accessed April 5, 2013.
4. Best BM, Capparelli EV, Diep H, et al. Pharmacokinetics of lopinavir/- ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr. 2011;58:385-391.
5. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25:393-399. (Pubitemid 36638188)
6. Williams RL, Chen ML, Hauck WW. Equivalence approaches. Clin Pharmacol Ther. 2002;72:229-237.
7. la Porte CJ, Schippers EF, Van Der Ende ME, et al. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications. AIDS. 2005;19:1105-1107. (Pubitemid 40961153)
8. Rakhmanina N, van den AJ, Baghdassarian A, et al. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009;53:2532-2538.
9. Pinto JCE, Mirochnick M, Warshaw M, et al; ftIPt. Pharmacokinetics of Lopinavir/ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines: Interim Results from IMPAACT P1083. Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, Georgia, US, 2013.
10. Rakhmanina NY, Neely MN, Van Schaik RH, et al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit. 2011;33:417-424.
11. Sharkey I, Boddy AV, Wallace H, et al. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer. 2001;85:23-28. (Pubitemid 32695711)
12. Bruguerolle B. Chronopharmacokinetics. Clin Pharmacokinet. 1998;35(2): 83-94.